AnaBios

About:

AnaBios provides contract research services for biotechnology and pharmaceutical industries.

Website: http://www.anabios.com

Top Investors: Ampersand Capital Partners, Tech Coast Angels, Keiretsu Forum, Principia SGR, Rady Venture Fund

Description:

AnaBios specializes in enabling human-focused drug discovery. As a CRO, AnaBios provides products and services for every stage of drug discovery. Through proprietary technology based on the use of human donor organs and tissues, it studies ex vivo human responses to drugs and further investigate the molecular and functional basis of relevant human physiology. Its research focuses primarily on the areas of high, unmet medical need, including cardiac disease and safety, pain, PKD kidney disease, and neurodegeneration. In partnership with Fortune 500 pharmaceutical companies, contract research organizations, and universities, the company's mission is to develop therapeutic advancements to help patients live longer, healthier, and more productive lives.

Total Funding Amount:

$19.3M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

San Diego, California, United States

Founded Date:

2009-01-01

Contact Email:

web(AT)anabios.com

Founders:

Jack Reynolds, Paul Miller

Number of Employees:

11-50

Last Funding Date:

2022-06-07

IPO Status:

Private

Industries:

© 2025 bioDAO.ai